Memorial Sloan Kettering Cancer Center

Where you’re treated first, matters. To make an appointment: 877-871-9362

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

We're excited to share Memorial Sloan Kettering Cancer Center (MSK)'s bold new advertising campaign “This Is What We Do.”

From a jazz musician whose life was saved by precision oncology, to a prostate cancer patient who has become an advocate for early detection, the stories we share throughout this campaign reflect our shared mission and the extraordinary outcomes we achieve together.

🔹 This is treatment on a cellular level. ​

🔹 This is care on a personal level. ​

🔹 This is hope on another level. ​

When someone receives a cancer diagnosis, we want them to know exactly what to do next: come to MSK. And when patients choose MSK, they’re choosing better, longer lives.

Learn more: https://t.co/SOGuFiUIGs

[The ASCO Post @ASCOPost]

🆕 #ASCO26 data in unresectable #HCC.

Ghassan K. Abou-Alfa, MD, PhD, FASCO, of @MSKCancerCenter discusses efficacy and safety findings from the phase III EMERALD-3 trial evaluating immunotherapy-based combinations with TACE.

🎥 Watch here: https://t.co/UFnzr7tCwp

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Congratulations to MSK's @Joshua_M_Weiss for being selected as a 2026 @CureMelanoma Grant Recipient! 🎉

[Melanoma Research Foundation @CureMelanoma]

We are proud to announce this year's outstanding Resident/Fellow Research Grant Awardees! Each of the 12 awardees selected are enabling innovative research for the cutaneous and rare melanoma subtypes that will advance the melanoma treatment landscape.

Grantees will explore topics ranging from vision loss after plaque radiotherapy for uveal melanoma, trends in acral melanoma, how circadian rhythms and immunotherapy outcomes are improved by light therapy and more.

View the MRF's funded researcher webpage to learn more and stay tuned for our awardee spotlights through the #MRFResearchWednesday campaign -- https://t.co/bjmC4UyZov

[Rebecca Scalabrino, DO @DrScalabrino]

Congratulations to our @MSKCancerCenter graduating body imaging fellows and cardiac imaging 🫀fellow!

[The ASCO Post @ASCOPost]

🆕 #ASCO26 data in dedifferentiated #liposarcoma.

Mark A. Dickson, MD, of @MSKCancerCenter, discusses SARC041 findings showing a statistically significant progression-free survival benefit with abemaciclib in advanced dedifferentiated liposarcoma.

🎥: https://t.co/tRNjK9esU6

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Thank you to everyone who participated in Memorial Sloan Kettering Cancer Center (MSK)'s #NYCforMSK and made the event so special.

On May 29, 35 iconic New York City brands came together to celebrate MSK’s 142nd anniversary and support lifesaving research and care.

Thank you to all of our partners and for everyone who shopped, donated, or even brought your pup to Madison Avenue, every act of generosity made a difference.

Learn more and donate here: https://t.co/ixkoUKKkPO

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Congratulations to Dr. Martin Weiser, who has been selected to serve serve as the next Chair of the Department of Surgery at MSK.

Dr. Weiser currently holds the Stuart H.Q. Quan Chair in Colorectal Surgery, is a world-renowned academic colorectal surgeon, and has held a number of important leadership roles in his 25 years on the faculty at MSK, including serving for the past 10 months as the Acting Department Chair.

Join us in welcoming Dr. Weiser to the role of Chair of the Department of Surgery by commenting below. 👏

[SEOM @_SEOM]

🏙️ Desde Chicago, en #ASCO26 @ASCO
⭕️ Vídeo de highlights #CáncerdePulmón en https://t.co/qgi4oDJ2nf
🩺 El Dr. Jaime Rubio, de @MSKCancerCenter, resume las novedades más relevantes: avances en terapias dirigidas para RET, ALK y EGFR (LIBRETTO-432, LORIN, CROWN y WU-KONG28), nuevos datos de inmunoterapia en HARMONi-6 y estrategias innovadoras con ADCs en enfermedad metastásica
#OncoNexion26 👇🏻

[Trinity St James's Cancer Institute @CancerInstIRE]

A landmark moment for pancreatic cancer, these findings highlight what transformative progress can look like. Congratulations to @EileenMOReilly & team @MSKCancerCenter advancing this research driving forward a new standard of care in a disease that has long needed breakthroughs

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Missed some of the research presented by MSK experts at #ASCO26?

We've rounded up selected highlights spanning sarcoma, liver cancer, lung cancer, prostate cancer, blood cancers, and more: https://t.co/wSL2tNgIAn

[Amy Xu, MD PhD @AmyXuMDPhD]

🧬 Can tumor genomics be used to personalize radiation dose?

Grateful to present results from our phase II trial on dose de-escalated radiation therapy for ATM altered tumors at #ASCO2026

Great to see ☢️ #Radiation in the early-phase #PrecisionOncology space!

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Presented at #ASCO26 and published in @NEJM, findings from the phase 3 RASolute 302 trial showed that #daraxonrasib significantly improved overall survival and progression-free survival compared with chemotherapy in previously treated metastatic pancreatic cancer.

MSK's @EileenMOReilly was among the leaders of this research.

[World News Tonight @ABCWorldNews]

New data from the company Revolution Medicines shows people with advanced pancreatic cancer who took daraxonrasib nearly doubled their overall survival. David Muir has details on the clinical trial. https://t.co/eHElMjnCBc

[ASCO @ASCO]

#ASCO26 truly embodied the theme of translating science into global patient outcomes. We are grateful to the ~46,000 attendees, all working tirelessly to conquer cancer together! A heartfelt thanks to all. 💗 We can’t wait to see you next year at #ASCO27!

[Amy Xu, MD PhD @AmyXuMDPhD]

✨ Inspiring to see @imrtlee representing ☢️ radiation oncology on the ASCO main stage.

Practice changing work reducing treatment toxicities and integrating radiographic biomarkers to personalize radiation

@MSK_RadOnc @MSKCancerCenter
#ASCO26 #RadOnc

[Yelena Y. Janjigian MD @YJanjigianMD]

Are you an early-career pathologist 🦠 looking to break into translational cancer research? Join our GEC accelerator 🚀team at drive the next generation of therapies for GE cancer. Pathology. Biomarkers. Clinical trials. Discovery. Apply here:
https://t.co/TPRyMRHUvo

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

An important moment for sarcoma research at #ASCO26. 👏

Congratulations to MSK’s Dr. Mark Dickson and the SARC041 investigators on the plenary presentation of these findings.

[Patrick Schöffski @schoffski]

Liposarcoma in the holy grail of oncology - the Plenary Session at the ASCO Annual Meeting 2026. Congratulations to Mark A. Dickson and all SARC041 investigators!

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Findings published in @NEJM and featured at #ASCO26 showed that #daraxonrasib significantly improved overall survival and progression-free survival compared with chemotherapy in previously treated metastatic #pancreaticcancer.

We’re proud of MSK’s contribution to this research, including the work of @EileenMOReilly and colleagues.

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Insights from yesterday’s session with MSK’s @GABOUALFA at #ASCO26 ⬇️

[HemOnc Today @HemOncToday]

🤝 #Tremelimumab & #durvalumab with transarterial chemoembolization may help address an unmet need in advanced #LiverCancer, #ASCO26 data show.

💬 “I am beyond excited to see that there are more options for our patients,” @GABOUALFA @MSKCancerCenter says. https://t.co/AszG2O7PTc

[Trinity St James's Cancer Institute @CancerInstIRE]

Exciting momentum in precision oncology, congratulations to @MSKCancerCenter @MichaelMayMD on advancing three first‑line metastatic KRAS inhibitor trials opening at @MSKCancerCenter in the coming weeks. A powerful signal of what’s ahead, with many more studies on the horizon.

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Highlighting research co-led by MSK gastrointestinal medical oncologist @EileenMOReilly presented at #ASCO26. ⬇️

[CBS News @CBSNews]

New drug nearly doubles survival rates in some pancreatic cancer patients, study says. https://t.co/JwBOFRx5Vj